Furthermore, the major oncogenic signaling pathways frequently activated in cancers are proven to regulate GLI transcription and activity independent of SMO (see Section 3.2.1 and Section 3.2.2), potentially explaining why SMO inhibitors may be ineffective in producing meaningful tumor responses in most solid tumors despite the expression of GLI proteins in these tumors. The gene discussed is SMO; the disease is cancer.